167 related articles for article (PubMed ID: 35961615)
21. Dupilumab for treatment of severe atopic dermatitis in a heart transplant recipient.
Hamid RN; Bomar L; Strowd L
Cutis; 2019 Jun; 103(6):E1-E2. PubMed ID: 31348459
[No Abstract] [Full Text] [Related]
22. Evaluation of innate lymphoid cells and their subsets in atopic dermatitis patients with and without dupilumab therapy.
Čelakovská J; Čermáková E; Boudkova P; Krejsek J
J Dermatolog Treat; 2024 Dec; 35(1):2299721. PubMed ID: 38174384
[No Abstract] [Full Text] [Related]
23. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
[TBL] [Abstract][Full Text] [Related]
24. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study.
Pezzolo E; Rossi M; Caroppo F; Bianchelli T; Belloni Fortina A; Giacchetti A; Calzavara Pinton P; Naldi L
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e757-e759. PubMed ID: 36662631
[No Abstract] [Full Text] [Related]
25. Extending dupilumab dosing intervals in atopic dermatitis: A prospective observational study in a South European tertiary hospital.
Valente C; Farinha P; Duarte B
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):e193-e194. PubMed ID: 37731014
[No Abstract] [Full Text] [Related]
26. Dupilumab provides rapid improvement for morphologic variants of paediatric atopic dermatitis: A case series.
Kim JW; Kim M; Ahn GS; Na JI
Indian J Dermatol Venereol Leprol; 2022; 88(6):834-839. PubMed ID: 36331828
[No Abstract] [Full Text] [Related]
27. Severe atopic dermatitis in a patient with Loeys-Dietz syndrome treated with dupilumab.
Gkalpakiotis S; Maresova T
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e70-e72. PubMed ID: 35964299
[No Abstract] [Full Text] [Related]
28. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients.
Ludriksone L; Elsner P; Schliemann S
J Dtsch Dermatol Ges; 2019 Dec; 17(12):1278-1280. PubMed ID: 31829527
[No Abstract] [Full Text] [Related]
29. Dupilumab for moderate-severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States.
Emmerich VK; Williams JA; Hrin ML; Feldman SR; Strowd LC
Int J Dermatol; 2024 Apr; 63(4):524-525. PubMed ID: 38093434
[No Abstract] [Full Text] [Related]
30. Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab.
Mazzoni D; Lobo Y; Levitt D; Wheller L
Pediatr Dermatol; 2022 Jul; 39(4):606-608. PubMed ID: 35575257
[TBL] [Abstract][Full Text] [Related]
31. Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab.
Cho MK; Shin JU; Kim DH; Lee HJ
Clin Exp Dermatol; 2022 Dec; 47(12):2303-2305. PubMed ID: 36006169
[TBL] [Abstract][Full Text] [Related]
32. A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab.
D'Adamio S; Massaro A; Biocca S; Bianchi L; Talamonti M; Galluzzo M
Clin Exp Dermatol; 2020 Aug; 45(6):809-810. PubMed ID: 32472943
[No Abstract] [Full Text] [Related]
33. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
Lor M; Villa N; Holland V
Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
[TBL] [Abstract][Full Text] [Related]
34. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
35. Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study.
Lasheras-Pérez MA; Palacios-Diaz RD; González-Delgado VA; Cobreros LV; Pereira-Resquin Galván GO; Miquel-Miquel J; Labrandero Hoyos C; Zaragoza Ninet V; Melgosa Ramos FJ; Sánchez-Motilla JM; Navarro-Blanco F; Martín-Torregrosa D; Botella-Estrada R; Rodríguez-Serna M
Int J Dermatol; 2024 Mar; 63(3):402-404. PubMed ID: 38229523
[No Abstract] [Full Text] [Related]
36. Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.
Blauvelt A
JAMA Dermatol; 2024 Mar; 160(3):370. PubMed ID: 38353963
[No Abstract] [Full Text] [Related]
37. Atopic keratoconjunctivitis alleviated with dupilumab.
Chen J; Bielory L
Ann Allergy Asthma Immunol; 2022 Sep; 129(3):375-376. PubMed ID: 35671933
[No Abstract] [Full Text] [Related]
38. Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: A nationwide US study.
Schoder K; Zhu Y; Schneeweiss S; Merola JF; Savage TJ; Gibbs LR; Schneeweiss MC
J Am Acad Dermatol; 2023 Jul; 89(1):178-181. PubMed ID: 36905959
[No Abstract] [Full Text] [Related]
39. Superimposed linear atopic dermatitis treated with dupilumab.
Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
[TBL] [Abstract][Full Text] [Related]
40. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
